TD Cowen Reiterates Buy Rating on Kalvista Pharmaceuticals Inc (KALV)

December 3, 2025 1:15 PM EST Send to a Friend
TD Cowen analyst Stacy Ku reiterated a Buy rating and $30.00 price target on Kalvista Pharmaceuticals Inc (NASDAQ: KALV).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login